Ethinylestradiol/drospirenone

Ethinylestradiol/drospirenone
	Ethinylestradiol
	Drospirenone
Combination of
Ethinylestradiol	Estrogen
Drospirenone	Progestogen; Progestin; Antimineralocorticoid; Antiandrogen
Names
Trade names	With 30 μg ethinylestradiol: Yasmin, others; With 20 μg ethinylestradiol: Yaz, Yasminelle, others
Other names	EE/DRSP
Clinical data
Drug class	Estrogen; Progestin; Progestogen; Antimineralocorticoid; Antiandrogen
Pregnancy; category	AU: B3; US: N (Not classified yet); ;
Routes of; use	By mouth
External links
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a601050
Legal
License data	US DailyMed: Drospirenone_and_estradiol;
Legal status	US: ℞-only ;
Identifiers
CAS Number	164017-31-6;
KEGG	D09741;
ATC code	G03FA17 (WHO) ;

Ethinylestradiol/drospirenone (EE/DRSP), sold under the brand name Yasmin among others, is a combination of ethinylestradiol (EE), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used as a birth control pill to prevent pregnancy in women.^[2]^[3]^[4]^[5] It is also indicated for the treatment of moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea (painful menstruation) in women.^[3] The medication is taken by mouth and contains 30 μg EE and 3 mg DRSP per tablet (brand names Yasmin, others) or 20 μg EE and 3 mg DRSP per tablet (brand names Yaz, Yasminelle, Nikki, others).^[4]^[5] A formulation with levomefolic acid (vitamin B₉) has also been marketed (brand names Beyaz, Safyral, others), with similar indications.^[6]^[7] EE/DRSP is marketed widely throughout the world.^[8]In 2017, it was the 98th most commonly prescribed medication in the United States, with more than eight million prescriptions.^[9]^[10]

Society and culture

In 2017, it was the 98th most commonly prescribed medication in the United States, with more than eight million prescriptions.^[9]^[10]

↑ ^1.0 ^1.1 "Drospirenone / estradiol (Angeliq) Use During Pregnancy". Drugs.com. 6 September 2018. Archived from the original on 18 March 2020. Retrieved 18 March 2020.
↑ "Archive copy". Archived from the original on 2021-08-28. Retrieved 2021-03-02.{{cite web}}: CS1 maint: archived copy as title (link)
↑ ^3.0 ^3.1 "Archive copy". Archived from the original on 2019-12-23. Retrieved 2021-03-02.{{cite web}}: CS1 maint: archived copy as title (link)
↑ ^4.0 ^4.1 "Archive copy" (PDF). Archived (PDF) from the original on 2021-04-02. Retrieved 2021-03-02.{{cite web}}: CS1 maint: archived copy as title (link)
↑ ^5.0 ^5.1 "Yaz" (PDF). Archived from the original (PDF) on October 31, 2017. Retrieved October 31, 2017.
↑ "Archive copy". Archived from the original on 2019-12-23. Retrieved 2021-03-02.{{cite web}}: CS1 maint: archived copy as title (link)
↑ "Archive copy" (PDF). Archived (PDF) from the original on 2021-03-30. Retrieved 2021-03-02.{{cite web}}: CS1 maint: archived copy as title (link)
↑ "Archive copy". Archived from the original on 2020-11-29. Retrieved 2021-03-02.{{cite web}}: CS1 maint: archived copy as title (link)
↑ ^9.0 ^9.1 "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
↑ ^10.0 ^10.1 "Drospirenone; Ethinyl Estradiol - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.

"Drospirenone mixture with estradiol". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2020-03-18. Retrieved 2021-03-02.

This drug article relating to the genito-urinary system is a stub. You can help MDWiki by expanding it.